TCGA-XF-AAMW-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.311432326
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- TGF_BETA_SIGNALING+0.540
- PROTEIN_SECRETION+0.470
- INTERFERON_GAMMA_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- ANGIOGENESIS+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- HEDGEHOG_SIGNALING+0.410
- MITOTIC_SPINDLE+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.410
Top 10 suppressed
- BILE_ACID_METABOLISM-0.330
- FATTY_ACID_METABOLISM-0.260
- PEROXISOME-0.210
- KRAS_SIGNALING_DN-0.200
- OXIDATIVE_PHOSPHORYLATION-0.170
- SPERMATOGENESIS-0.170
- MYOGENESIS-0.120
- CHOLESTEROL_HOMEOSTASIS-0.090
- XENOBIOTIC_METABOLISM-0.090
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.936 |
| 2 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.899 |
| 3 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.892 |
| 4 | SRR934760 | — | — | 0.891 |
| 5 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.890 |
| 6 | TCGA-XF-A9T4-01A-11R-A39I-07 | — | — | 0.887 |
| 7 | TCGA-HQ-A5NE-01A-12R-A28M-07 | — | — | 0.886 |
| 8 | SRR934956 | — | — | 0.885 |
| 9 | SRR934881 | — | — | 0.883 |
| 10 | TCGA-FD-A6TK-01A-42R-A33J-07 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.540 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |